| Description | Olodanrigan is a novel orally available and highly selective antagonist of angiotensin II type 2 receptor (AT2R). |
| Synonyms | PD-126055, EMA401, EMA 401, EMA401 sodium, EMA-401, PD 126055 |
| molecular weight | 530.576 |
| Molecular formula | C32H29NNaO5 |
| CAS | 1316755-17-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Nascimento OJ, Pessoa BL, Orsini M, Ribeiro P, Davidovich E, Pupe C, Filho PM, Dornas RM, Masiero L, Bittencourt J, Bastos VH. Neuropathic Pain Treatment: Still a Challenge. Neurol Int. 2016 Jun 29;8(2):6322. doi: 10.4081/ni.2016.6322. eCollection 2016 Jun 15. PubMed PMID: 27441065; PubMed Central PMCID: PMC4935814. 2. Pessoa BL, Escudeiro G, Nascimento OJ. Emerging Treatments for Neuropathic Pain. Curr Pain Headache Rep. 2015 Dec;19(12):56. doi: 10.1007/s11916-015-0530-z. Review. PubMed PMID: 26530058. 3. Sałat K, Kowalczyk P, Gryzło B, Jakubowska A, Kulig K. New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs. 2014 Aug;23(8):1093-104. doi: 10.1517/13543784.2014.916688. Epub 2014 Jun 4. Review. PubMed PMID: 24896842. |